Title : Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.

Pub. Date : 2015 Dec

PMID : 26475277






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-beta. Glatiramer Acetate interferon beta 1 Homo sapiens
2 The ratio of the costs during interferon-beta was 1.5 times the costs during glatiramer acetate; thus, a fixed budget of 5,000,000$ would enable 1,070 patients to be treated with glatiramer acetate and only 706 patients with interferon-beta. Glatiramer Acetate interferon beta 1 Homo sapiens